AMGEN INC shareholders Q3 2023

AMGEN INC's ticker is AMGN and the CUSIP is 031162100. A total of 2,449 filers reported holding AMGEN INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.5%.

AMGEN INC shareholders Q3 2023
NameSharesValueWeighting ↓
JLB & ASSOCIATES INC 70,181$18,861,8462.96%
OAK ASSOCIATES LTD /OH/ 128,638$34,572,7572.88%
HFR Wealth Management, LLC 36,510$9,8122.87%
Lodestone Wealth Management LLC 14,947$4,017,2672.81%
ELLERSON GROUP INC /ADV 11,195$3,008,7682.80%
Harvest Portfolios Group Inc. 219,556$59,007,8712.79%
O'Brien Greene & Co. Inc 28,098$7,551,6182.76%
ASAHI LIFE ASSET MANAGEMENT CO., LTD. 29,242$7,859,080,0002.71%
Buckley Wealth Management, LLC 26,765$7,193,3612.69%
Crescent Sterling, Ltd. 9,451$2,540,0512.69%
Steigerwald, Gordon & Koch Inc. 65,447$17,589,5632.68%
Loudon Investment Management, LLC 14,142$3,800,8042.61%
CULLINAN ASSOCIATES INC 166,855$44,843,9502.61%
Peloton Wealth Strategists 20,753$5,5782.57%
BENEDICT FINANCIAL ADVISORS INC 32,822$8,821,3562.55%
Argyle Capital Management Inc. 25,746$6,919,4952.54%
Aristotle Capital Management, LLC 4,353,169$1,169,957,5382.51%
Beutel, Goodman & Co Ltd. 1,575,642$423,4692.50%
Navalign, LLC 24,468$6,576,1062.50%
Palisade Asset Management, LLC 76,295$20,505,0442.49%
About AMGEN INC

Amgen Inc. is a biotechnology company that specializes in the development of innovative medicines for the treatment of serious illnesses. The company has a strong track record of success, with a portfolio of products that includes some of the most widely used and effective drugs in the world.

One of Amgen's most important products is Enbrel, a drug used to treat rheumatoid arthritis and other autoimmune diseases. Enbrel has been a major success for the company, generating billions of dollars in revenue each year.

Amgen is also a leader in the development of cancer treatments, with a number of promising drugs in its pipeline. The company's cancer drugs are designed to target specific types of cancer cells, which can help to minimize side effects and improve patient outcomes.

In addition to its focus on drug development, Amgen is also committed to sustainability and social responsibility. The company has implemented a number of initiatives to reduce its environmental impact, and it has also established programs to support education and healthcare in underserved communities.

Overall, Amgen is a company with a strong track record of success and a commitment to innovation and social responsibility. With a portfolio of products that includes some of the most effective drugs in the world, Amgen is well positioned for continued growth and success in the years ahead.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists AMGEN INC's shareholders in Q3 2023. To view AMGEN INC's shareholder history, click here.